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Diabetes mellitus is a metabolic disorder that is characterized by high glucose levels which 
may result in damage to various organs, including the heart, kidneys, and eyes. Several theo-
ries by which high glucose levels causes dysfunction of  these organs have been proposed, in-
cluding the aldose reductase, advanced glycation endproduct, reactive oxygen intermediates, 
and protein kinase C theory1. Multiple studies have shown a relationship between the degree 
of  glucose levels and the development of  complications, including diabetic eye disease. The 
Diabetes Control and Complication Trial (DCCT) and the UK Prospective Diabetes Study 
(UKPDS) have provided evidence that intensive glucose control reduces the risk of  visual loss 
in patients with type 1 and type 2 diabetes, respectively2,3. Despite the growing understand-
ing of  the complex processes involved in diabetic complications, diabetic retinopathy (DR) 
remains a leading cause of  vision loss in working-aged people4. DR is characterized by capil-
lary closure and retinal vascular hyperpermeability. Early histological signs of  DR include 
the loss of  pericytes and capillary basement membrane thickening. These processes may 
lead to outpouchings of  capillaries and the formation of  microaneurysms5. Micro-aneurysms 
are frequently the first clinically visible hint of  DR during eye examination. The number of  
micro-aneurysms is associated with DR progression and breakdown of  the inner endothelial 
blood-retinal barrier (BRB), characterized by hard exudates and localized areas of  retinal vas-
cular hyperpermeability6,7. The leakage of  fluid into the retinal tissue may exceed clearance, 
leading to a major cause of  visual loss in diabetic patients: diabetic macular edema (DME).
dIabetIc macular edema 
The pathogenesis of  DME is not fully understood. Although the breakdown of  the BRB is 
considered to be a major mechanism in the development of  DME, other mechanisms may 
include capillary non-perfusion, neuronal damage, and alterations of  the vitreous gel9. Vas-
cular Endothelial Growth Factor (VEGF) is a major mediator of  proangiogenic factors which 
may produce DME by altering endothelial tight junctions and transcellular flow5. Intraocular 
delivery of  anti-VEGF therapies are now used widely in the treatment of  DME. However, 
it is estimated that about 50% of  DME patients are refractory to anti-VEGF therapies10,11. 
At present, robust biomarkers to identify which DME patients are potential good and non-
responders to anti-VEGF therapies have not been established.
necessIty of bIomarkers for dr
The global rise in diabetes will result in 552 million individuals being affected by this chronic 
sight-threatening disease by the year 203012. By the year 2050, 1 in 3 persons in the United 
States are projected to have diabetes, with approximately half  having some degree of  DR 
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at any point in time13. Thus, ocular complications from diabetes are a major and expanding 
public health concern. There is a critical need to identify biomarkers for DR14. Although anti-
VEGF agents are effective, there is a need for the substantial proportion of  patients who do 
not respond completely to anti-VEGF therapy11. One difficulty that prevents the development 
of  new treatments is the identification of  robust biomarkers of  DR that could help define 
targets for new therapies or provide more effective management strategies15. Another is the 
prolonged period needed to assess changes in vision and progression of  disease by fundus 
photography. Associations found to date are generally not sensitive or specific enough to be 
reliable biomarkers for DR16.
ImagIng bIomarkers for dr
Imaging techniques in DR include fundus photography, fluorescein angiography (FA) and 
optical coherence tomography (OCT). FA visualizes areas of  retinal hyperpermeability, but 
these areas are difficult to quantitate and often show a low correlation with retinal thickening 
on OCT17. Retinal features visualized by noninvasive imaging techniques such as OCT may be 
potential candidates for biomarkers of  DME. The definition of  a biomarker is ‘a characteristic 
that is objectively measured and evaluated as an indicator of  normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention’18. They 
may be part of  the pathophysiological pathway of  the endpoint of  interest19. OCT generates 
high-resolution cross-sectional images by measuring the echo time delay and magnitude of  
back-reflected light. It is a noninvasive imaging modality that allows quantitative measure-
ments of  retinal thickness, as well as evaluation of  anatomic lesions different from retinal 
thickening20. Specific OCT patterns have been reported to be predictive of  outcome after 
anti-VEGF therapy. Patients with cystoid macular edema (CME) pattern have been found to 
achieve better visual acuity and greater changes in retinal thickness after anti-VEGF therapy, 
while patients with diffuse pattern have been reported to exhibit a less favorable outcome21-23. 
In addition to specific OCT patterns, anatomic characteristics such as the presence of  highly 
reflective spots, disruption of  inner/outer retinal layers and intraretinal cysts have been 
suggested to be relevant features in predicting the response of  DME patients to anti-VEGF 
therapies24-28. 
novel bIomarkers for dr
Aiello, King, and colleagues have identified VEGF as an important mediator in the devel-
opment of  DME by proteomic analysis of  the vitreous fluid of  patients with DR33. Other 
potential mechanisms and biomarkers of  DR may be found in other and more accessible 








1processes involved in DR has offered approaches to select candidate circulating biomarkers 
based on pathogenic mechanism and structural damage. Recently, a number of  circulating 
biomarkers associated with pathogenic mechanisms and structural retinal tissue damage of  
DR have been independently and significantly associated with DR34-39. Endothelial progenitor 
cells are circulating cells that have been suggested to play roles in the regeneration of  vessel 
damage and may be involved in the pathogenesis of  DR35,36,40,41. Other candidate biomarkers 
are related to structural damage of  the retina in DR34,38,39,42. However, little is known about 
the potential value of  these biomarkers in patients with DME. In addition to further research 
investigating the potential of  these biomarkers, it is essential to investigate potential VEGF-
independent mechanisms of  DME, such as the plasma kallikrein kinin system (KKS). 
kallIkreIn kInIn system
The KKS has been discovered by Feener and colleagues as a potential mediator of  BRB 
loss and VEGF-independent mechanism of  DME43-49. Plasma kallikrein is activated by the 
coagulation factor XIIa, which is released by the contact system during inflammation and 
bleeding47. Once generated, plasma kallikrein divides high molecular weight kininogen to 
produce bradykinin, which can stimulate vasoactive hormones (e.g. nitric oxide) that influ-
ence the BRB48. Components of  the KKS, including plasma kallikrein and factor XII, have 
been identified in the vitreous fluid of  patients with DME44. These findings suggest that 
components of  the KKS in plasma may be potential biomarkers in patients with DME. 
aIm of the thesIs
The aim of  the thesis is to identify potential novel biomarkers for DR. Identification of  po-
tential novel biomarkers for DR could contribute to the definition of  targets for new therapies 
and provide more effective management strategies for DR.
outlIne of the thesIs
Components of  the KKS may be potential biomarkers for DR. In Chapter 1a, we review the 
role of  the KKS in diabetes and the mechanisms that contribute to KKS activation. The physi-
ological actions of  components of  the KKS are described. The review provides an overview 
of  the factors that have been associated with activation of  the KKS and the functions that 
have been supported by clinical data. In addition, genetic studies of  the KKS gene and the 
biochemical functions are summarized. Future directions and new strategies to monitor KKS 
activity are also discussed. As discussed above, the biological effects of  the KKS are primarily 
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mediated by bradykinin. Chapter 1b characterizes the effects of  bradykinin on retinal struc-
ture and proteome of  the rat retina. This chapter concludes with Chapter 1c, which examines 
the associations between DR, kidney disease, and cardiovascular disease by characterizing 
individuals with type 1 diabetes in the United States and Finland.
The aim of  study in Chapter 2 was to examine potential imaging biomarkers for DR. In 
chapter 2a, we examine the predictive value of  OCT patterns and retinal features on visual 
outcomes and retinal thickness of  patients with DME receiving anti-VEGF treatment. This 
is important, since there are no methods available in clinical practice to assess which pa-
tients with DME are good-responders and non-responders to anti-VEGF therapy. Within the 
prospective, multicenter BRDME (comparing the effectiveness and costs of  Bevacizumab to 
Ranibizumab in patients with Diabetic Macular Edema) study, we evaluated the potential of  
retinal features visualized by OCT as biomarkers in patients with DME that receive anti-VEGF 
therapies. Although diabetic neuroretinal abnormalities have been previously described, such 
as thinning of  inner retinal layers50, changes in individual retinal layers have not been fully 
explored across multiple decades of  diabetes duration. In chapter 2b, we assessed retinal 
layer thicknesses on OCT on 1413 eyes of  776 patients across a wide range of  age, duration 
of  diabetes, and DR severity.
In Chapter 3a, we determined whether specific circulating biomarkers could be used as 
potential markers for patients with DME that receive anti-VEGF therapy. The candidate bio-
markers were selected based on literature on structural damage and pathogenic mechanism 
of  DR and included mRNA levels of  CD34+, CD133+, rhodopsin, RPE65, and retinoschisin. 
Blood samples were collected at baseline in a cohort of  patients from the BRDME study 
and OCT images and visual acuity were analyzed during anti-VEGF treatment to assess the 
associations between candidate markers and changes in retinal thickness and visual acuity. 
Chapter 3b focuses on the retinal and vitreous protein profiles from participants of  the Joslin 
50-Year Medalist Study. The Joslin Medalist Study characterized over 1000 people with type 
1 diabetes duration of  50 years or more. Over 35% of  these individuals exhibit only no-mild 
diabetic retinopathy (DR), independent of  glycemic control, suggesting the presence of  en-
dogenous protective factors against DR. The goal of  the study was to identify these protective 
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